Table 7.
Clinical features of AFF cases published in the literature
| Journal | Age/Gender | Primary disease | Exposure to other BMA | Duration of denosumab treatment | Diagnosis | Operation (treatment) |
|---|---|---|---|---|---|---|
| Yang et al. The oncologist (2017) | 70/F | Breast Ca. | Alendronate, Risedronate | 23 months | Rt. AFF | Intramedullary rod placement |
| Ota et al. Breast Cancer (2017) | 73/F | Breast Ca. | Zoledronic acid | 54 months | Bilateral AFF | |
| Sugihara et al. Clin Nucl Med (2018) | 59/F | Breast Ca. | None | 4 years (48 months) | Rt. impending AFF or AFSR | |
| Koizumi et al. Clin Nucl Med (2017) | 53/F | Thyroid Ca. | Bisphosphonate | 1.5 years (18 months) | Lt. impending AFF | |
| Tateiwa et al. Journal of orthopaedic surgery (2017) | 52/F | Breast Ca. | Pamidronate, Zoledronate | 2 years and 3 months (27 months) | Bilateral AFF | Intramedullary nail was placed |
| Austin et al. Acta Orthopedica (2017) | 75/F |
Breast Ca. NSCLC |
None | 2 years (24 months) | Bilateral AFF | Intramedullary fixation |
| 86/M | Prostate Ca. | None | 3.5 years (42 months) | Rt. AFF |